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Cerebral aneurysms (CAs) have a high prevalence and can cause a lethal subarachnoid hemorrhage. Currently, CAs can only be
treated with invasive surgical procedures. To unravel the underlying mechanisms of CA formation and to develop new therapeutic
drugs for CAs, animal models of CA have been established, modiﬁed, and analyzed. Experimental ﬁndings from these models
have clariﬁed some of the potential mechanisms of CA formation, especially the relationship between hemodynamic stress and
chronic inﬂammation. Increased hemodynamic stress acting at the site of bifurcation of cerebral arteries triggers an inﬂammatory
response mediated by various proinﬂammatory molecules in arterial walls, inducing pathological changes in the models similar to
those observed in the walls of human CAs. Findings from animal studies have provided new insights into CA formation and may
contribute to the development of new therapeutic drugs for CAs.
1.Introduction
Vascular diseases represent an important problem due to
their potential severity and increasing prevalence. Many
series of studies, especially those on atherosclerosis, have
contributed to reduce the mortality rate of vascular diseases
and to improve the patients’ quality life [1]. Unfortunately,
it is not a case in subarachnoid hemorrhage (SAH), which
is a potentially lethal disease with a mortality rate of up to
50% and is responsible for more than 30,000 patient deaths
per year in the United States [2, 3]. Furthermore, SAH can
cause a considerable cognitive impairment that results in
restricted social activity, even in patients who recover well
and successfully return to their daily lives [4]. Therefore, the
prevention of SAH is a socially important issue. A cerebral
aneurysm (CA) is the primary cause of spontaneous SAH
and can be found in approximately 1%–5% of the general
population [3, 5–7]. Currently, surgical procedures such as
microsurgical clipping and endovascular coiling are the only
therapeuticmodalitiesthoughttopreventtheruptureofpre-
existing CAs [6]. However, because of the inescapable risk
of complications, surgical treatment is recommended only
for a selected group of patients with an estimated high risk
of rupture. This means that many patients with CAs are
followed without any eﬀective treatment, while managing
potential risk factors for rupture [5, 8]. Given the severity
of SAH after the rupture of CAs, there is a strong demand for
the development of a medical treatment for CA.
In the present paper, we review the current knowledge of
theunderlyingmechanismsofCAformation,mainlyderived
from animal models and discuss the development, clinical
relevance, usefulness, and future potential of animal models
of CA.
2. FindingsandLimitationsof HumanStudies
There is considerable interest in elucidating the underlying
mechanisms of CA formation in order to develop less
invasive medical treatments. For this purpose, many human
studies, including the histopathological analysis of surgically
dissected CAs or cerebral arteries, gene linkage analysis,
and epidemiological analysis, have been performed and2 Journal of Biomedicine and Biotechnology
achieved a measure of success. These studies have revealed
certain elements that may be important in the pathogenesis
of CAs. Here, a CA is characterized as the blooming of
cerebralarterialwalls,especiallyatthebifurcationsite,thatis
accompanied by the disruption of the internal elastic lamina
and degenerative changes in arterial walls represented by the
thinning of the media and the loss of medial smooth muscle
cells [9, 10].
Aneurismal SAH has a familial clustering or a diﬀerence
in race,suggesting the genetic inﬂuence. Certainly, genelink-
age analyses have identiﬁed some of the susceptibility loci or
genes that increase the risk for the development and rupture
of CAs [11–24]. Most identiﬁed genes are pro-inﬂammatory
genes or extracellular matrix-related genes, suggesting that
an inﬂammatory process or the turnover of the extracellular
matrix is actively involved in the pathogenesis of CAs.
Epidemiological analyses have identiﬁed some risk fac-
tors for the enlargement or rupture of CAs, most notably
hypertension [8, 25, 26], which increases the hemody-
namic stress at the bifurcation site of cerebral arteries and
potentially contributes to the formation of CAs through
the induction of mechanical damage in the arterial wall
[9]. These studies provided epidemiological support for
a hypothesis derived from the computational simulation
of blood ﬂow at a prospective CA formation site which
suggest that hemodynamic stress triggers CA formation
[27–30].
Histopathological studies of human CA tissues have
implicated the involvement of inﬂammatory processes in
the pathogenesis of CA. The increased expressions of pro-
inﬂammatory factors such as collagenolytic matrix met-
alloproteinases (MMPs) [31–33], vascular cell adhesion
molecule-1 (VCAM-1) [34], tumor necrosis factor-alpha
(TNF-α)[ 35], monocyte chemoattractant protein-1 (MCP-
1)[36],andmitogen-activatedproteinkinases(MAPKs)[37,
38] have been found in human CA walls using immunos-
taining, Western blot, or PCR analysis. Further, histological
studies also revealed the inﬁltration of macrophages and T
cells [34], complement or immunoglobulin deposition and
activation [34, 39], and apoptotic cell death in CA walls
[40, 41], suggesting the active involvement of inﬂammation
in CA formation.
As described above, studies using human samples have
contributed to the understanding of the underlying mech-
anisms of CA formation; however, these studies also have
several important limitations. First, microsurgical dissection
of CA may increase the rupture. Second, CA formation
is thought to be inﬂuenced by the genetic background as
in the Japanese and Finish populations which are known
to have a signiﬁcantly higher incidence of CAs than other
populations [4]. CAs can also exhibit familial clustering
[5, 8, 25]. Taken together, the complexity of this problem
may render the analysis of CA formation diﬃcult. Third,
we can only evaluate human CA samples at certain time
points, and we can not assess sequential changes of CA
formation. To overcome these limitations and to more
systematically examine the underlying mechanisms of CA
formation, animal models of CAs have been demanded and
developed.
3. Overview of Animal Models of CA
Animal models can reduce the complexity of genetic analysis
because of their homogeneous genetics and bring ease of
manipulationthroughtheavailabilityofmolecularbiological
tools. Currently, there are 2 major classes of animal models
of CA. First are the animal models that are used to evaluate
the underlying mechanisms of CA formation, which will be
described in detail later on in this review. Second are the
modelsmainlyusedtodetermine thetechnicalproﬁciencyof
endovascular devices or to assess histopathological changes
after endovascular treatment; however, this class is not used
to determine the underlying mechanisms of CA formation.
These models are surgically induced by creating a venous
pouch mainly in the carotid artery of dogs or pigs [42–45].
4. Animal Models of CA Induced by
IncreasedHemodynamics
Several studies attempted to develop an animal model of
CA in which the histopathological features of human CA
were reproduced, for example, the disruption of the internal
elastic lamina and the degeneration of the media, before
Hashimoto et al. reported their ﬁrst rat model of CA [46].
Previous attempts involved the use of various compounds
including a nitrogen mustard and cyanoacrylate, in order
to degenerate the arterial walls, for example, [47–49], but
failed to induce CAs with similar pathological characteristics
to human ones.
Hashimoto et al. successfully induced CAs at the bifur-
cation site of cerebral arteries of rats in 1978 by increasing
hemodynamics on the basis of the hypothesis that CA was
formed at fragile arterial walls loaded with a high hemody-
namic stress [46]. They thoughtfully used the lathyrogen, β-
aminopropionitrile(BAPN),whichinhibitsthecross-linking
of collagen and elastin ﬁbers [50, 51], to weaken arterial
walls. The oral administration of BAPN to animals degen-
erates arterial walls and, as a result, occasionally induces
an arterial dissection (angiolathyrism) [52, 53]. To further
increase hemodynamic stress with systemic hypertension,
theyligatedtheunilateralcommoncarotidartery,performed
a unilateral nephrectomy, administered deoxycorticosterone,
and increased salt intake in BAPN-treated rats. CAs were
thus spontaneously induced at the bifurcation sites of
the cerebral arteries [46]. Histopathological studies of the
induced CAs demonstrated that their pathological features
were in accordance with those of human CAs [54]. This
group also examined the eﬀects of hemodynamic stress
on CA formation by comparing the bilateral or unilateral
ligation of carotid artery and conﬁrmed that hemodynamic
stress greatly inﬂuenced CA formation [29].
The CA rat model has since undergone several modiﬁca-
tions. Currently, CAs are induced by the unilateral ligation
of the common carotid artery with induced hypertension
by the unilateral ligation of the renal artery and increased
salt intake with or without BAPN treatment (Figure 1).
BAPN treatment enhances the incidence of CA formation
and the size of the induced CAs [46, 55]; however, it
also disturbs normal collagen synthesis and the turnoverJournal of Biomedicine and Biotechnology 3
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Figure 1: Cerebral aneurysm (CA) formation in the rat model. (a) The method for CA induction. As illustrated, the unilateral common
carotid artery (CCA) is ligated to induce a compensatory increase in cerebral blood ﬂow in the contralateral internal carotid artery (ICA).
As a result of increased hemodynamics, a CA is induced at the anterior cerebral artery-(ACA-) olfactory artery (OA) bifurcation (indicated
by the boxed region). MCA: middle cerebral artery. (b) Macroscopic image of the dissected ACA-OA bifurcation indicated as the boxed
region in (a). Note that a CA is induced at this bifurcation (arrow). (c, d) Histopathological examination of induced CA by Elastica van
Gieson staining. Higher magniﬁed image of CA walls is shown in (d). Note that the disruption of the internal elastic lamina (arrow) and the
degeneration of the media, which are histopathological features of human CA walls, are observed. Bar: 50μm.
of the extracellular matrix. Further, Nagata et al. have also
demonstrated that BAPN treatment and salt overloading
have a synergistic eﬀect on CA formation [56].
A mouse model of CA was successfully established in
2002 by the unilateral ligation of the carotid artery and
induced hypertension [57]. The histopathological exami-
nation of murine CAs by electron microscopy shows the
disrupted internal elastic lamina and degenerative changes
in the media, as observed in human CAs [57]. As mice
are more resistant to induced hypertension and vascular
inﬂammation, more time is needed to induce CAs and
their incidence is less than in the rat model [57, 58].
Technical advancements in molecular biology have enabled
the generation of genetically modiﬁed mice. Increased
availabilityofmolecularbiologicaltoolsinthisspeciesallows
us to genetically analyze the underlying mechanisms of CA
formation using various gene-deﬁcient mice. These mice are
particularly useful to analyze the contribution of particular
genes to disease pathogenesis.
Hashimoto et al. have also successfully induced CAs
in monkeys (Macaca fascicularis) by the ligation of the
common carotid artery and systemic hypertension with
BAPN treatment [59]. Histopathological studies revealed
that the CAs induced in primates had similar characteristics
as in human CAs [60]. The usage of the primate model is
limited due to ethical concerns; however, since rats and mice4 Journal of Biomedicine and Biotechnology
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Figure 2: Brief summary of animal models of CA used in recent experimental studies. A brief summary of animal models used in recent
experiments is shown. The particularities, advantages, and disadvantages of each model are as follows. ∗1: Induced hypertension can be
achieved by several methods such as the ligation of the renal artery, high salt diet intake, deoxycorticosterone treatment, and angiotensin II
injection. ∗2: This model is mainly used for the development of endovascular devices and not for the analysis of the molecular mechanisms
of CA formation. ∗3: The new bifurcation is created at the carotid artery by side-to-end ligation. This model is suitable for the analysis of
hemodynamics-induced CAs, but the hemodynamic stress is greater than in the intracranial arteries where the CAs are formed. ∗4: CAs can
be induced with a high frequency and with a low risk, but they seldom rupture. BAPN treatment enlarges the size of the induced CAs. ∗5:
BAPN intake or local elastase injection is essential for the induction of CAs. Lipopolysaccharide can also enhance CA formation and huge
CAs can sometimes be observed. ∗6: It takes over 1 year to induce CAs, but their incidence is high. ∗7: It is necessary to perform bilateral
oophorectomy to eﬀectively induce CAs. ∗8: Large CAs are frequently induced in the posterior circulation. This model has the potential to
be used in studies linking hemodynamics and molecular expression. ∗9: Bilateral CCA ligation results in high mortality, but can induce large
CAs in the posterior circulation. CCA: common carotid artery.
are more resistant to arterial inﬂammation than primates
and monkeys and humans are closely related species, a
monkey model may still be necessary in some situations.
Severalothergroupshavealsoappliedtheinducedhyper-
tension/lathyrism model [30, 52, 61–66]. We have mainly
used male rats or mice as CA models to exclude the inﬂuence
of sex hormones. Jamous et al. recently induced CAs in
female rats through carotid ligation, induced hypertension,
and bilateral oophorectomy [63]. The sex hormone estrogen
has a protective eﬀect on endothelial cell function and
may therefore inﬂuence CA formation [67]. Indeed, they
demonstrated that bilateral oophorectomy increased the size
of the induced CAs by decreasing the levels of estrogen [63].
Furthermore, they examined the protective eﬀect of estrogen
on CA formation by applying hormone replacement therapy
to their rat model and conﬁrmed that hormone replacement
therapy could attenuate the increased formation of CAs by
bilateral oophorectomy [62].
Gao et al. induced CAs in New Zealand white rabbits by
increasing hemodynamic stress through the bilateral ligation
of the carotid arteries [61]. He and his colleagues selected
rabbits because the arterial diameter of rats and mice is
too small to reproducibly perform a hydrokinetic analysis
of hemodynamics during CA formation. They demonstrated
that increased hemodynamic stress triggered CA formation
and that the induction of CAs was well correlated with the
increase of blood ﬂow in the basilar artery.
Meng et al., who was the corresponding author of Gao’s
paper, further reported the correlation of hemodynamic
stress with CA formation using a canine model [30]. They
induced CAs by surgically creating a new bifurcation site
using the carotid artery of dogs and measured the hemody-
namic stress in situ. As a result, the high wall shear stress
and high wall shear stress gradient induced pathological
changes resembling human CA, for example, the disruption
of the internal elastic lamina and the loss of medial smooth
musclecells[30].Thecaninemodelswereusedtounravelthe
correlation of hemodynamic stress with CA formation using
ad i ﬀerent concept than our models, which are designed to
study the molecular basis of CA formation.
We and other researchers have modiﬁed the present CA
models and tried to develop novel models that are designedJournal of Biomedicine and Biotechnology 5
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Figure 3: Proposed mechanisms of CA formation from human and animal studies. Proposed mechanisms of CA formation from human
and animal studies are summarized and illustrated.
to answer a question (Figure 2). In the near future, we hope
thatmoredesirablemodelsofCAswillbedevelopedtoreveal
the mechanisms of CA formation in more detail.
5.ExploratoryPathophysiology of
CAs fromAnimalStudies
Animal models of CA have provided us with insights into
the underlying mechanisms of CA formation, and we can
proposeahypothesisforthemolecularbasisofCAformation
from the experimental ﬁndings of animal models (Figure 3).
Here, we will summarize the experimental ﬁndings of CA
formation.
On the basis of the ﬁnding that inﬂammatory cells,
especially macrophages, are observed in CA walls in humans
[34], the inﬁltration of inﬂammatory cells in CA walls
was assessed using a rat model. The primary inﬂammatory
cells in rat CA walls are macrophages, in good agreement
with observations in human CA walls [68, 69], and their
numbergraduallyincreasesduringCAformation,suggesting
that macrophage-mediated inﬂammation may contribute
to CA formation [68]. Macrophages secrete various tissue-
destructive proteinases and cytokines, which can degenerate
the components of the extracellular matrix of arterial walls,
especially collagen and elastin, and are hypothesized to con-
tribute to CA formation, especially the enlargement of CAs
through the weakening of CA walls. Indeed, macrophages
secretecollagenolyticproteinases,MMP-2andMMP-9inCA
walls of rats [68, 70], and enhanced collagenolytic activity is
detectedinCAwallsofratmodelsbyinsituzymography[68,
69] or gelatin zymography [71–74]. Consistent with these
observations, the oral administration of MMP inhibitors to
rat models or a deﬁciency of MMP-9 results in the decreased
formation of CAs [68, 69]. Another group of proteinases,
cysteine cathepsins, are also upregulated in rat CA walls and
their activities are signiﬁcantly elevated in comparison with
those in control arterial walls [75]. A speciﬁc inhibitor of
cathepsins eﬀectively suppresses CA formation [75]. These
results suggest that proteinases actively participate in the
p a t h o g e n e s i so fC Aa n dp r o m o t eC Af o r m a t i o n .
Macrophages are recruited to inﬂammatory sites by
chemoattractants, for example, MCP-1 [76, 77]. In CA walls
of rat models, the expression of MCP-1 is upregulated in
intimal endothelial cells at the early stage of CA formation
[58] and in whole arterial walls, including inﬁltrating
inﬂammatory cells, at the late stage [58, 70]. These ﬁndings
are in accord with previous human studies in which the
expression of MCP-1 mRNA was conﬁrmed in human6 Journal of Biomedicine and Biotechnology
CA specimens by in situ hybridization [36]. Further, in
MCP-1-deﬁcient mice, in which macrophage inﬁltration
of CA walls is abolished, CA formation is inhibited with
the suppression of inﬂammation [58]. The upregulation of
various pro-inﬂammatory molecules in human CA walls has
been reported and gene microarray data also support these
observations [17, 78].
We identiﬁed the upregulation of pro-inﬂammatory
genes during CA formation in CA walls of rat models
using microarray analysis and adaptor-tagged competitive-
PCR analysis [79, 80]. Most of the upregulated genes can
be categorized as proteinases, cytokines, adhesion molecules,
reactive oxygen species, members of the apoptotic cas-
cade, and complements, suggesting that the inﬂammatory
response in arterial walls plays a crucial role in CA formation
[79].
The genetic contribution to CA formation has also been
examined using animal models. In rats, the upregulation of
reactive oxygen species-producing enzymes such as p47phox
[81], superoxide-related genes such as NOX4 or Rac1 [70],
cytokines such as interleukin-1β (IL-1β)[ 82], and inducible
nitric oxide synthase (iNOS) [83]i sc o n ﬁ r m e di nC Aw a l l s .
However, contradictory results for the contribution of the
renin-angiotensin system (RAS) in CA walls have been
reported. Tada et al. reported in the induced CA walls
of female rat models that the expression of angiotensin
converting enzyme (ACE) was upregulated as determined by
RT-PCR analysis, and the ﬁnal product of RAS, angiotensin
II production, was also increased in CA walls as determined
by immunostaining [70]. On the contrary, our group found
thatangiotensinIIreceptortype1(AT1R)wasnotinducedin
CA walls of male rats by immunostaining and, consistently,
the administration of an AT1R blocker (ARB) failed to
inhibit CA formation [84]. In human CA walls, Ohkuma et
al. reported the decreased expression of ACE and AT1R by
RT-PCR analysis and immunostaining [85]. It is not clear
whythesediﬀerencesoccurandfuturestudiesshouldaddress
this issue.
In mice, the role of a particular gene on CA formation
can be assessed more clearly by applying gene-deﬁcient
mice to the models. Mice deﬁcient in MMP-2 or -9 [69],
tissue inhibitor of MMP (TIMP)-1 or -2 [73], MCP-1 [58],
p47phox [55], toll-like receptor-4 (TLR-4) [86], NF-κBp 5 0
subunit [87], IL-1β [82], apolipoprotein E (ApoE) [88], or
iNOS [89] have been applied to CA models revealing the
involvement of each gene in the pathogenesis of CAs. In
summary, MMP-9, MCP-1, p47phox, TLR-4, NF-κBp 6 5
subunit, IL-1β, and iNOS promote CA formation, while
TIMP-1 and TIMP-2 suppresses CA formation.
These experimental results suggest that chronic inﬂam-
mation in arterial walls plays the important role in CA
formation. We have proposed that the transcription factor
NF-κB is a critical mediator due to its transcriptional
regulation of various pro-inﬂammatory genes in CA walls
including MMPs, iNOS, IL-1β, and MCP-1, which have been
shown to be involved in the pathogenesis of CA [58, 68, 82,
83, 87, 89]. NF-κB is phosphorylated and activated ﬁrst in
the endothelial cells of CA walls at the early stage of CA
formation and then throughout CA walls at the late stage
[88]. We have hypothesized that NF-κBa c t i v a t i o ni nt h e
endothelial cell layer is due to hemodynamic stress, which
is thought to be a trigger for CA formation [27, 29, 90–
94]. This hypothesis is in line with the experimental ﬁndings
that NF-κB is activated in endothelial cells by hemodynamic
stress in vitro [95] and that high hemodynamic stress
induces the expression of MMP-2, -9, iNOS, and IL-1β in
CA walls created in the carotid arteries of a canine model
[96]. The inhibition of NF-κB transcriptional activity by
decoy oligodeoxynucleotides [97] or a deﬁciency in the
p50 subunit of NF-κB results in the remarkable inhibition
of CA formation by the suppression of pro-inﬂammatory
gene expression and macrophage inﬁltration in CA walls,
suggesting the critical role of NF-κBa c t i v a t i o ni nC A
formation [88].
6. Limitationsof the ExistingCA Models and
the Necessity for Further Models
As described in the previous sections, animal models of
CA have been used to demonstrate some of the important
mechanisms of CA formation and identiﬁed therapeutic
targets for the treatment of human CAs (Figure 3); however,
there is a fundamental problem to be addressed in animal
models. It is beyond question that the rupture of CAs and
the subsequent SAH is a devastating event and should be
prevented; therefore, the prevention of CA rupture is a
critical target. For this reason, animal models of CAs are
needed where CAs have a high likelihood of spontaneous
rupture. Unfortunately, there are no established models
with this feature. In our rat models, the rupture rate is
only 3% during 3 months after CA induction. We have
preliminarilyexaminedseveralcompoundsandmodiﬁedthe
procedures to induce CAs; however, we failed to establish a
rat model with a high incidence of rupture and have never
observed the spontaneous rupture of CAs in mice. Recently,
Nuki et al. reported that they stereotaxically injected an
elastase into the basal cistern in combination with the
continuous infusion of angiotensin II to induce CAs in mice
[69]. In their report, these induced CAs in murine models
spontaneously ruptured, although the exact incidence of
rupturewasnotmadeclear[69].Therefore,itisessentialthat
an animal model is developed in which CAs spontaneously
and frequently rupture.
7. FuturePerspectives:From the Results of
AnimalStudiesto HumanTreatment
Extensive studies using animal models of CAs are, of
course, designed to unravel the underlying mechanisms of
CA formation and to establish new therapeutic drugs for
unruptured CAs in humans. As described in the previous
sections, we have identiﬁed NF-κB as one of the factors
closely related to CA formation and a potential therapeu-
tic target [87, 98, 99], therefore, we have examined the
preventive eﬀects of several drugs with anti-NF-κBa c t i v i t y
on the enlargement of CAs induced in a rat model [71,
72, 74, 81, 84]. Among several candidate drugs, the class
of statins, a powerful cholesterol-lowering drug, have beenJournal of Biomedicine and Biotechnology 7
found to eﬀectively prevent the enlargement of CAs induced
in rats [71, 74]. The oral administration of statin to rats
signiﬁcantly suppresses the expression of pro-inﬂammatory
genes in CA walls [74] through its anti-NF-κBe ﬀect well
known as a pleiotropic eﬀect [100]. As a result, the chronic
inﬂammationinCAwalls,transcriptionallyregulatedbyNF-
κB, is inhibited. These results, combined with experimental
ﬁndings indicating that chronic inﬂammation contributes
to CA formation, suggest that statin can suppress the
enlargement of CAs. In present models, we can not assess the
ruptureofCAsbecauseoftheirlowincidenceofspontaneous
rupture; however, statin eﬀectively prevents the degenerative
changes of CA walls, suggesting a preventive eﬀect of statin
on the rupture of CAs. Furthermore, we and others have
independently demonstrated that 3 diﬀerent kinds of statins
preventtheformationandenlargementofCAsinducedinrat
models, indicating that the preventive eﬀect of statins on the
enlargement of CAs is due to their class eﬀect [71, 74, 101].
These results suggest the therapeutic potential of statins
as drugs for CAs in humans. Based on these experimental
ﬁndings, a case-control study to examine the preventive
eﬀect of statins on the rupture of human CAs is currently
in progress. Other candidates as therapeutic drugs for CA
treatment, for example, Ibudilast or a phosphodiesterase-
4 inhibitor, have been examined using rat CA models with
focus on their anti-inﬂammatory eﬀects [66, 70, 102].
8. Conclusions
SAH caused by the rupture of a pre-existing CA is a poten-
tially devastating and socially restricting event. To unravel
the underlying mechanisms of CA formation and to develop
a new class of therapeutic drugs to prevent rupture, animal
models of CAs have been established. Experimental results
from animal models and ﬁndings from human specimens
haverevealedsomeoftheimportantmechanismsunderlying
CA formation. Increased hemodynamic stress at the bifurca-
tion site of the cerebral arteries is considered to play a crucial
role in CA formation by inducing inﬂammatory responses
in arterial walls. Inﬂammation in cerebral arterial walls
triggered by hemodynamic stress is considered to disrupt the
internal elastic lamina and degenerate the media. As a result
of the increased hemodynamic stress and inﬂammatory
responses in cerebral arteries, CA is induced. Through
recent experimental ﬁndings, we have identiﬁed NF-κBa s
a potential therapeutic target for CA. The inhibition of
NF-κB activity in animal models, signiﬁcantly suppress CA
formation, suggesting that anti-NF-κBd r u g sc a np o t e n t i a l l y
be therapeutic drugs for CAs. In the future, there is a
hope that, through increasing use and extensive studies by
animal models of CAs, the elucidation of the underlying
mechanisms of CA formation allows the pharmacological
prevention of SAH.
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